Forland, MG;
Ohrfelt, A;
Dalen, I;
Tysnes, O-B;
Blennow, K;
Zetterberg, H;
Pedersen, KF;
... Lange, J; + view all
(2018)
Evolution of cerebrospinal fluid total α-synuclein in Parkinson's disease.
Parkinsonism & Related Disorders
, 49
pp. 4-8.
10.1016/j.parkreldis.2018.01.018.
Preview |
Text
Zetterberg_Forland.pdf - Accepted Version Download (505kB) | Preview |
Abstract
Introduction: Cerebrospinal fluid (CSF) total α-synuclein is considered a potential biomarker for Parkinson's disease (PD), but little is known about the evolution of this marker during the course of the disease. Our objective was to investigate whether CSF total α-synuclein concentrations change over time and are associated with motor and cognitive function in PD. Methods: CSF total α-synuclein concentrations were quantified in 56 longitudinally followed PD patients, 27 of whom provided CSF repeatedly 2 and/or 4 years later. Another 18 subjects were included as controls. The samples were analyzed using two independent, validated ELISA methods: our recently developed and validated in-house ELISA and a commercial kit from BioLegend. Results: CSF total α-synuclein levels did not distinguish PD patients from controls, displayed no substantial changes during a period of up to 4 years, and did not predict subsequent motor or cognitive decline. These findings were consistent for both analytical methods. Conclusion: Our findings do not support the clinical utility of total α-synuclein as a single diagnostic or prognostic biomarker in PD.
Archive Staff Only
 |
View Item |
